Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAP-007: Pembrolizumab with or without lenvatinib in treatment-naive metastatic NSCLC (PD-L1 TPS ≥1%)
jRCT2080224599Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Pembrolizumab + lenvatinib with Pembrolizumab + placebo (2 arms). Primary endpoint: Overall survival. Started Mar 2019; status: completed.
02
Drugs
pembrolizumablenvatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080224599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224599.